Healthcare resources utilisation in primary progressive multiple sclerosis

被引:0
作者
Carlo Piccinni
Giulia Ronconi
Silvia Calabria
Letizia Dondi
Emanuele Forcesi
Elisa Rossi
Antonella Pedrini
Nello Martini
机构
[1] CORE srl—Collaborative Outcome Research,Health Care Department
[2] CINECA—Interuniversity Consortium,undefined
来源
Neurological Sciences | 2018年 / 39卷
关键词
Primary progressive multiple sclerosis; Real-world evidence; Burden of disease; Italy; Administrative databases;
D O I
暂无
中图分类号
学科分类号
摘要
Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This study was aimed to evaluate the burden of PPMS in Italy with healthcare resources utilisation and costs for Italian National Health System (INHS). A 2-year cross-sectional analysis of real-world data collected in the ARCO database, covering > 10 million Italian inhabitants, was performed. From a cohort of patients affected by MS in 2014, those supposedly affected by PPMS were defined by the concurrent matching of absence of disease-modifying treatments and use of rehabilitation services. Any other drug prescriptions, outpatient services and hospitalisations were analysed in 2015 for each subject. The average annual cost per patient was provided both for each expenditure item and by integrating these. Of 13,253,591 inhabitants, 18,453 resulted affected by MS (prevalence 139 × 100,000). Of these, 1849 agreed with additional criteria to identify PPMS (10% of MS population). The 26.8% of these experienced at least one admission in 1 year, 97.3% used at least one outpatient service and 94.3% received at least one reimbursed drug. In the perspective of INHS, PPMS generated an average annual cost of € 3783 per person: 49% for hospitalisations, 28% for outpatient services and 23% for drugs. This study provides a reliable estimation of the PPMS burden in Italy, in terms of healthcare utilisation and direct costs. These findings could be useful to estimate the changes in health expenditure following the incoming of new drugs to treat PPMS with increase of pharmaceutical cost and potential decrease of rehabilitation and hospitalisation costs.
引用
收藏
页码:1169 / 1174
页数:5
相关论文
共 162 条
[1]  
Browne P(2014)Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity Neurology 83 1022-1024
[2]  
Chandraratna D(2017)Estimated prevalence of multiple sclerosis in Italy in 2015 Neurol Sci 38 473-479
[3]  
Angood C(2002)The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy J Neurol 249 152-163
[4]  
Tremlett H(2006)Costs and quality of life of multiple sclerosis in Italy Eur J Health Econ 7 S45-S54
[5]  
Baker C(2012)Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy Mult Scler 18 29-34
[6]  
Taylor BV(2015)Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs Neurol Sci 36 227-234
[7]  
Thompson AJ(2017)New insights into the burden and costs of multiple sclerosis in Europe: results for Italy Mult Scler 23 104-116
[8]  
Battaglia MA(2012)The economic cost of brain disorders in Europe Eur J Neurol 19 155-162
[9]  
Bezzini D(2012)Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 123 627-638
[10]  
Amato MP(2007)Primary-progressive multiple sclerosis Lancet Neurol 6 903-912